Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BIBF 1120|BEHAVIORAL: Phone Call
Sponsor: M.D. Anderson Cancer Center
Collaborators: Boehringer Ingelheim